Immunogenic cell death after combined treatment with radiation and ATR inhibitors is dually regulated by apoptotic caspases.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2023
Historique:
received: 06 01 2023
accepted: 15 05 2023
medline: 26 6 2023
pubmed: 22 6 2023
entrez: 22 6 2023
Statut: epublish

Résumé

Inhibitors of the ATR kinase act as radiosensitizers through abrogating the G2 checkpoint and reducing DNA repair. Recent studies suggest that ATR inhibitors can also increase radiation-induced antitumor immunity, but the underlying immunomodulating mechanisms remain poorly understood. Moreover, it is poorly known how such immune effects relate to different death pathways such as caspase-dependent apoptosis. Here we address whether ATR inhibition in combination with irradiation may increase the presentation of hallmark factors of immunogenic cell death (ICD), and to what extent caspase activation regulates this response. Human lung cancer and osteosarcoma cell lines (SW900, H1975, H460, U2OS) were treated with X-rays and ATR inhibitors (VE822; AZD6738) in the absence and presence of a pan-caspase inhibitor. The ICD hallmarks HMGB1 release, ATP secretion and calreticulin surface-presentation were assessed by immunoblotting of growth medium, the Extracellular release of HMGB1 was increased in all the cell lines at 72 hours after the combined treatment with radiation and ATR inhibitors, relative to mock treatment or cells treated with radiation alone. The HMGB1 release correlated largely - but not strictly - with loss of plasma membrane integrity, and was suppressed by addition of the caspase inhibitor. However, one cell line showed HMGB1 release despite caspase inhibition, and in this cell line caspase inhibition induced pMLKL, a marker for necroptosis. ATP secretion occurred already at 48 hours after the co-treatment and did clearly not correlate with loss of plasma membrane integrity. Addition of pan-caspase inhibition further increased the ATP secretion. Surface-presentation of calreticulin was increased at 24-72 hours after irradiation, but not further increased by either ATR or caspase inhibition. These results show that ATR inhibition can increase the presentation of two out of three ICD hallmark factors from irradiated human cancer cells. Moreover, caspase activation distinctly affects each of the hallmark factors, and therefore likely plays a dual role in tumor immunogenicity by promoting both immunostimulatory and -suppressive effects.

Identifiants

pubmed: 37346039
doi: 10.3389/fimmu.2023.1138920
pmc: PMC10279842
doi:

Substances chimiques

Caspases EC 3.4.22.-
HMGB1 Protein 0
Calreticulin 0
Caspase Inhibitors 0
Protein Kinase Inhibitors 0
Adenosine Triphosphate 8L70Q75FXE
ATR protein, human EC 2.7.11.1
Ataxia Telangiectasia Mutated Proteins EC 2.7.11.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1138920

Informations de copyright

Copyright © 2023 Eek Mariampillai, Hauge, Kongsrud and Syljuåsen.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Front Oncol. 2022 Aug 29;12:971959
pubmed: 36106115
Cell Death Dis. 2020 Nov 26;11(11):1013
pubmed: 33243969
J Immunother Cancer. 2020 May;8(1):
pubmed: 32461345
Radiat Oncol. 2020 Nov 4;15(1):254
pubmed: 33148287
Cancer Res. 1995 Apr 15;55(8):1639-42
pubmed: 7712467
Int J Clin Oncol. 2020 May;25(5):801-809
pubmed: 32246277
Curr Res Pharmacol Drug Discov. 2021 Feb 05;2:100017
pubmed: 34909652
Front Oncol. 2022 Oct 28;12:981332
pubmed: 36387237
Oncoimmunology. 2019 Aug 26;8(11):e1655964
pubmed: 31646105
J Immunother Cancer. 2022 Mar;10(3):
pubmed: 35314434
Clin Transl Radiat Oncol. 2018 Jun 08;12:16-20
pubmed: 30073210
Surgery. 1999 Aug;126(2):389-92
pubmed: 10455911
Sci Immunol. 2022 Jun 10;7(72):eabl9330
pubmed: 35687697
J Clin Invest. 2018 Aug 31;128(9):3926-3940
pubmed: 29952768
Nat Med. 2011 Jul 03;17(7):860-6
pubmed: 21725296
Nat Med. 2007 Jan;13(1):54-61
pubmed: 17187072
Cell Death Differ. 2014 Jan;21(1):79-91
pubmed: 23852373
Oncoimmunology. 2014 Dec 13;3(9):e955691
pubmed: 25941621
Cancers (Basel). 2017 Apr 27;9(5):
pubmed: 28448462
Cell Death Dis. 2021 Jul 16;12(8):713
pubmed: 34272360
Science. 1999 Jul 9;285(5425):248-51
pubmed: 10398600
Int J Mol Sci. 2019 Jun 29;20(13):
pubmed: 31261963
Oncogene. 2004 Apr 12;23(16):2825-37
pubmed: 15077146
J Exp Med. 2006 Jul 10;203(7):1637-42
pubmed: 16818669
Annu Rev Immunol. 1994;12:991-1045
pubmed: 8011301
Cancer Res. 1995 Apr 15;55(8):1643-8
pubmed: 7712468
Immunity. 2008 Jul 18;29(1):21-32
pubmed: 18631454
Front Genet. 2015 Feb 27;6:70
pubmed: 25774168
J Mol Cell Biol. 2021 Dec 30;13(10):739-747
pubmed: 34718659
Cells. 2021 Sep 27;10(10):
pubmed: 34685531
Oncoimmunology. 2014 Apr 25;3:e28518
pubmed: 25071979
Cell Rep. 2020 Sep 1;32(9):108080
pubmed: 32877684
Mol Cell. 2017 Jan 19;65(2):336-346
pubmed: 28089683
Front Oncol. 2021 Mar 30;11:638873
pubmed: 33859942
JCI Insight. 2023 Feb 22;8(4):
pubmed: 36810257
Nat Rev Cancer. 2012 Dec;12(12):860-75
pubmed: 23151605
Annu Rev Med. 2022 Jan 27;73:231-250
pubmed: 34644155
Cancers (Basel). 2021 Jul 28;13(15):
pubmed: 34359691
Oncogene. 2003 Sep 1;22(37):5834-47
pubmed: 12947390
EMBO Rep. 2002 Oct;3(10):995-1001
pubmed: 12231511
Exp Mol Med. 2022 Feb;54(2):91-102
pubmed: 35217834
Cancer Commun (Lond). 2023 Apr;43(4):435-454
pubmed: 36855844
Clin Cancer Res. 2019 Jun 1;25(11):3392-3403
pubmed: 30770349
Nat Immunol. 2020 May;21(5):546-554
pubmed: 32231300
EMBO J. 2009 Mar 4;28(5):578-90
pubmed: 19165151
EMBO J. 2020 Jul 15;39(14):e104036
pubmed: 32484965
Cancer Chemother Pharmacol. 2022 Jan;89(1):59-69
pubmed: 34698902
Am J Physiol Cell Physiol. 2006 Dec;291(6):C1318-25
pubmed: 16855214
FEBS J. 2022 Jul;289(14):4098-4111
pubmed: 34089572
Cell Death Dis. 2015 May 14;6:e1761
pubmed: 25973681
Oncoimmunology. 2022 Sep 13;11(1):2117321
pubmed: 36117525
Cancers (Basel). 2021 Feb 28;13(5):
pubmed: 33671073
Cell Death Differ. 2018 Mar;25(3):486-541
pubmed: 29362479
Semin Cancer Biol. 2022 Nov;86(Pt 2):737-747
pubmed: 35405340
Adv Exp Med Biol. 2017;1036:65-79
pubmed: 29275465
Oncotarget. 2014 Jan 30;5(2):403-16
pubmed: 24480782

Auteurs

Adrian Eek Mariampillai (A)

Department of Radiation Biology, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.

Sissel Hauge (S)

Department of Radiation Biology, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.

Karoline Kongsrud (K)

Department of Radiation Biology, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.

Randi G Syljuåsen (RG)

Department of Radiation Biology, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH